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Abstract
Background: Although there are many studies discussing the etiological and pathological factors leading to both,
acute and chronic tendon injuries, the pathophysiology of tendon injuries is still not clearly understood. Although
most lesions are uncomplicated, treatment is long and unsatisfactory due to the poor vascularity of tendon tissue.
Platelet mediator concentrate (PMC) contains many growth factors derived from platelets, which can promote
wound healing. In this study we investigate the effects of PMC on tenocyte proliferation and differentiation in order
to provide an experimental basis for tissue regeneration strategies and to develop new treatment concepts.
Methods: Using enzyme linked immunosorbent assay (ELISA) we were able to quantify the several growth factors
and cytokines found in PMC. Tenocytes were isolated both from human and from mouse Achilles tendons and
stimulated with PMC. CyQuant® and Cell Titer Blue® assays were carried out to analyze tendon growth and viability
at different concentrations of PMC. Real time RT-PCR was used to analyze tenocyte gene expression with or without
PMC treatment. Immunohistochemistry was carried out to detect the tenocyte-specific antibody tenomodulin
(TNMD) and scleraxis (SCX).
Results: We were able to detect numerous mediators such as platelet derived growth factor BB (PDGF-BB),
interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-α), transforming growth
factor beta 1 (TGF-ß1), and bone morphogenetic proteins 2, 4 and 7 (BMP-4, BMP-2, BMP-7) in PMC. It was possible
to show a positive effect of PMC on human tendon cell growth and viability in a dose-dependent manner.
Furthermore, PMC treatment led to induction of gene expression of scleraxis (SCX), type I collagen A 1 (Col1A1) and
TNMD by tenocytes.
Conclusions: We suggest that the use of autologous PMC may be a suitable addition to conventional tendon
therapy that is capable of increasing and optimizing tendon healing and reducing the risk of recurrence.
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Background
Between three and five million people worldwide suffer ten-
don and ligament injuries every year [1]. Achilles tendino-
pathy is often related to specific sports injuries caused by
inappropriate biomechanical stress. It can also occur
through non-usage due to sedentary lifestyles. Furthermore
the occurrence in association with metabolic disorders such
as arthritis and diabetes, or from the use of medications
such as corticosteroids or certain antibiotics, underscores
the multifactorial etiology of tendinopathy [2].
Tendon ruptures are classified as either spontaneous,
traumatic, or open laceration. Previous histological ex-
aminations of spontaneously ruptured Achilles tendons
have elucidated degenerative changes in a majority of
cases [3]. Degenerative changes in the Achilles tendon
emerge primarily in regions with hypo- or avascularity,
such as at the insertion or tendon-waist [4]. Multiple
microtrauma lead to high expression of VEGF, which is
characteristic of the painful pathogenesis of tendon rup-
tures [5]. VEGF-mediated neoangiogenesis is found in
areas with neovessels and accompanying nerves together
with synthesis of matrix metalloproteinases (MMP) [6].
VEGF is not the only molecule to regulate tendon devel-
opment and healing. Others include SCX, PDGF-BB and
TGF-ß1 [7]. In general, growth factors play an important
role in the several phases of tendon healing. There is an
inflammatory, a proliferative, and a remodeling phase [7].
Tendon ruptures are currently managed either conserva-
tively or surgically [8]. Regardless of treatment method,
however, there is no guarantee that full function can be
regained, and a recurrence risk after surgical treatment per-
sists (1.7–5.4 %) [9, 10]. The ability of tendons to self-repair
is limited. Treatment is thus long and unsatisfactory, and
only 70 % of patients regain full previous tendon function
[10]. Repaired tendon characterized by scarring, and its bio-
mechanical properties are altered and inferior [11].
New approaches to treatment employ alternative strat-
egies such as stem cell repair, platelet rich plasma (PRP)
or other orthobiologics, either through direct application
or in conjunction with scaffolding [1, 12, 13]. Studies in-
dicate that autologous growth factors, in the form of
PRP, have an accelerated curative effect especially in
treating ruptured Achilles tendons [14–16]. PRP delivers
local autologous bioactive agents which influence the
tendon healing phases, inflammation, extracellular
matrix (ECM) synthesis and angiogenesis [17]. Platelet-
released growth factors (PRGF) have a similar effect.
This is a concentrated form of platelets without both
erythrocytes and leukocytes [16].
However, there is no standardized method of plasma
preparation. Randomized clinical trials are few [13]. The
Advanced Tissue Regeneration Kit (ATR®) manufactured
by Curasan AG Kleinostheim offers a standardized, labor-
free approach. It delivers a centrifugation-free method of
preparing human platelet mediator concentrates (PMC)
[18]. The kid can be used chairside in the visiting room
and is ready in a few hours. The present study detects dif-
ferent mediators in PMC and compares then with plasma
and serum. Furthermore the effects of PMC on human
and mouse tenocytes are elucidated in vitro.
Methods
Substantial growth factors were detected and quantified
in PMC. The levels of these growth factors in PMC were
compared to those of plasma and serum. The PMC were
used as stimuli to treat tenocytes.
PMC preparation
The ATR® kit is a sterilized, disposable medical product.
PMC were prepared as described in the guide and other
work by Schmolz et al. [18]. First 8 ml whole peripheral
blood from healthy, mainly male donors between the
ages of 20–35 was drawn into a 10 ml syringe. There it
was mixed with a combination of an anticoagulant and a
sedimentation accelerator (Solutions A and B). This
blood mixture rests for approximately 50 to 60 min in
an upright position as provided for by the kit, at room
temperature. The plasma supernatant containing the
platelets was then transferred into a 5 ml syringe. 3.5 ml
supernatant was then injected into the top opening of
the ATR system, where the platelets pass through differ-
ent filter systems. Solution C, which contains a washing
buffer, was then added. It eliminated any anticoagulants or
sedimentation fragment. Solution D was the last to be
injected. It has triggerd the release of mediators from the
platelets. The injection proceed in two steps. First 1 ml of
solution D was added and incubated at room temperature
for 10 min. Then the rest of the solution was pressed onto
the filter. The triple-concentrated PMC, containing only
the mediators, was collected at the lateral opening of the
kit using another syringe. We aliquoted the PMC in
200 μL Eppis and stored it at −80 °C.
Serum and plasma preparation
Blood from 14 human volunteers (18–45 years, 5 male,
9 female) was collected, from which whole blood (10 ml)
was kept to clot at room temperature for approximately
10 h and centrifuged at 2,000 × g for 10 min at 37 °C to
the serum. Plasma was prepared from whole blood from
same volunteers in a second syringe containing anti-
coagulant (citrate) and centrifuged in the same way.
Each serum and plasma sample was stored in aliquots at
−20 °C until further use (i.e., ELISA analyses).
Isolation of human tenocytes
Tenocytes were isolated from the Achilles tendon of
postmortem human donors under written declarations
of consent obtained from each donor enrolled in this
Arslan et al. BMC Musculoskeletal Disorders  (2016) 17:307 Page 2 of 9
study; these are on record at the Department of Anat-
omy. The tendon was washed with phosphate buffered
saline (PBS) and cut into pieces after careful removal of
the epitendineum. To remove the fibroblasts, the tissues
were pretreated with 0.5 % trypsin for 5 min at 37 °C.
Subsequently, the tendon pieces were washed and culti-
vated in Dulbecco’s modified Eagle’s medium (DMEM)
(GIBCO®, Invitrogen) containing 50 % fetal calf serum
(FCS) and 1 % penicillin streptomycin Fungizone (PSF)
[19]. After approximately two weeks, tenocytes continu-
ously migrated from this explant and adhered to petri
dishes. After 70–80 % confluence, cells were removed
using 1 % trypsin (5×; Gibco, Invitrogen) and cultivated
in culture medium (DMEM) (GIBCO®, Invitrogen) con-
taining 100 unit/ml penicillin, 100 μg/ml streptomycin
(GIBCO®, Invitrogen) and 10 % FCS. The tenocytes were
used from the second through fourth passages.
Isolation of mouse tenocytes
Tenocytes were isolated from the Achilles tendons of mice
between two and three days after birth (balb/mouse;
charles river). First, the skin and epitendineum were care-
fully removed from the Achilles tendon. Tissue was seg-
mented and treated with 1 % trypsin (5×; Gibco,
Invitrogen) for five minutes at 37 °C. After washing with
PBS, the tendon was cultivated in culture medium con-
taining 50 % FCS [20]. The concentration of the FCS was
reduced to 10 % FCS after one week. After two weeks cul-
tivation, a 70–80 % confluence had been achieved. Passa-
ging was then performed with 1 % trypsin in PBS.
Stimulation of cells with PCM
After the second passage, the adherent monolayer was
trypsinized and seeded in Petri dishes at 105 cells/cm2
cells, and then cultivated in culture medium. One day
prior to stimulation, the concentration medium was re-
placed by serum-starved medium containing 1 % FCS.
Stimulation with PMC ensued at concentrations of 0, 1,
5 and 10 % in FCS starved medium for 3 h and 24 h.
Cell proliferation and cell viability assay
The CyQuant® assay Kit (Invitrogen GmbH, Darmstadt,
Germany) was employed to measure in vitro tenocyte cell
proliferation according to the manufacturer’s protocol. The
CellTiter-Blue® Cell viability assay (Promega Corporation,
Madison, USA) was used to evaluate cell viability in re-
sponse to various concentrations of PCM. Human teno-
cytes treated according to the stimulation protocol above
were used for both assays. The results were normalized to
control group without PMC addition.
Analysis of mediator composition of PMC
The concentrations of different mediators like PDGF-
BB, VEGF, TGF-β1, BMP-2, BMP-4, BMP-7, TNF-α and
IL-6 were assessed in PCM, serum and plasma using
commercially available ELISA kits (R&D Systems and
Peprotech).
Real time RT-PCR
RNA was extracted with NucleoSpin RNA XS (Machery
Nagel, Germany) according to the manufacturer’s protocol.
The RNA concentration was determined by photometric
analysis using the NanoDrop 1000 system (PEQLAB
Biotechnologie GmbH). 1 μg of total RNA was then
digested with DNase I (Roche GmbH) and transcribed into
cDNA by reverse transcription with RevertAidTM reverse
transcriptase (Fermentas Life Sciences). Real time PCRs
were processed in triplicate using the ABI StepOnePlusTM
apparatus (Applied Biosystems) in a total volume of 15 μl
containing 70–100 ng of cDNA, gene specific primers and
SYBR Green I reagent (Applied Biosystems). The target
genes tenomodulin (TNMD), scleraxis (SCX) and Col-
lagen1A1 (Col1A1) (Qiagen, Germantown, MD, USA) were
measured. Beta-2-microglobulin (B2M) served as internal
control.
Immunofluorescence
For immunofluorescence, tenocytes were seeded and
cultivated on cover slides. Having been washed thrice
with PBS, cells were fixed in Zamboni for 10 min and
washed again with PBS. Cells were stored until use in
PBS at 4 °C. The cells were then washed thrice with
0.1 % Triton X in PBS for 5–10 min and then thrice with
TRIS for 5 min. Afterwards cells were blocked with
1.5 % bovine serum albumin (BSA) in TRIS for 20 min.
Immunostaining against tenomodulin (Santa Cruz Bio-
technology, CA, USA; sc-49352) (1:50 in Tris-buffered
saline, 2 h) and scleraxis (Santa Cruz Biotechnology, CA,
USA; sc-49352) (1:50 in Tris-buffered saline, 2 h) was
used to characterize the differentiated phenotype of the
tenocytes. Phalloidin Alexa Fluor 488 (life technologies,
A12379, 1:20) and Alexa Fluor 594 (life technologies, A
21431, 1: 350) (1:200 in 1.5 % BSA in TRIS, 2 h) was
used subsequently. A bisBenzimide staining was used to
counterstain the nuclei. To analyze the expression of
SCX and TNMD in tenocytes, three (3) images from
each sample were captured randomly. Images were made
using a Keyence BZ-9000 microscope with a 20× Plan-
Flour El NA 0.45 Ph1 objective and equal exposure time.
Expression of SCX and TNMD were determined using
the freely available software FIJI [21]. Contoures of
tained cells were followed with the freeform tool to de-
fine regions of interest (ROI-1) and their mean grey
value was determined. In parallel, the mean grey value of
the cell-near background was determined (ROI-2) and
substracted from ROI-1 to calculate the mean overall
value per picture. The values were normalized to the
control group.
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Statistical analysis
Results were expressed as the mean ± standard error
(SEM) and compared using a one-way ANOVA,
Dunnett’s post hoc test. To compare the growth factor
content of PMC, plasma and serum, we used a one-way
ANOVA, Bonferroni test. Differences were considered
significant at p ≤ 0.05. All statistical graphs and analyses
were created with GraphPad Prism 5.0 (GraphPad
Software, La Jolla, CA, USA).
Results
Various mediators were detected using ELISA in PMC
and compared with serum and plasma (Fig. 1). In PMC
the PDGF-BB, hVEGF, TGF- β1 and BMP-4 concentra-
tions were substantially elevated as compared to serum
und plasma. At the same time the IL-6 and TNF-α levels
were significantly lower than in serum and plasma. Data
showed no significant difference in BMP-2 and BMP-7
levels of PMC as compared to plasma and serum.
Cell viability was determined by using a CellTiter-
Blue® Cell viability assay (Fig. 2). The cell viability rate
improved with application of PMC as a media supple-
ment at 3 h and 24 h. There was no effect after 3 h, but
any concentration of PMC tested led to increased cell
viability after 24. PMC increased the cell viability of
tenocytes positively, in a concentration dependent man-
ner, after 24 h (B) of stimulation (1.0 ± 0.036, 1.41 ±
0.049, 1.50 ± 0.044, 1.69 ± 0.069, 1.70 ± 0.076 and 1.51 ±
0.043 by 0, 1, 2.5, 5, 10 and 20 % PCM, n = 6, p ≤ 0.05);
but no effect appeared after 6 h treatment (A).
The proliferative effect of PMC on human Achilles
tenocytes was tested in a CyQuant assay (Fig. 3). PMC
concentrations of 0, 1, 2.5, 5, 10 and 20 % were tested. Sig-
nificantly increased cell proliferation was observed in
tenocytes at each PMC concentrations used (1.00 ± 0.21,
1.25 ± 0.035, 1.33 ± 0.034, 1.41 ± 0.057, 1.61 ± 0.085 and
1.56 ± 0.10 by 0, 1, 2.5, 5, 10 and 20 % PCM, 24 h, n = 14,
p ≤ 0.05).
Fig. 1 Concentrations of growth factors in PMC, serum and plasma. In PMC and serum the PDGF-BB concentration was substantially elevated compared
to plasma (3767 ± 593 pg/ml and 1715 ± 399 pg/ml compared to 283 ± 55.8 pg/ml, n= 7, p< 0.05 ). The concentrations of VEGF, TGF-ß and BMP-4 were
likewise increased in PMC and serum (VEGF: 464 ± 82.3 pg/ml and 185 ± 20.5 pg/ml to 185 ± 20.5 pg/ml, n= 14; TGF-β: 3022 ± 304 pg/ml and 1936 ±
192 pg/ml to 515 ± 45.8, n= 7; BMP-4: 230 ± 48.9 pg/ml and 147 ± 11.7 pg/ml to 77.7 ± 9.58, n= 9, respectively, p< 0.05). No significant differences were
measured between BMP-2 and BMP-7 levels in PMC, serum, or plasma (BMP-2: 77.7 ± 9.58 pg/ml, 943 ± 290 pg/ml and 943 ± 290; respectively; BMP-7:
3059 ± 272 pg/ml, 3059 ± 272 pg/ml and 2577 ± 670 pg/ml; respectively, n= 6, p< 0.05). The levels of both inflammatory cytokine IL-6 and TNF-α were
significantly increased in serum as compared to PMC and plasma (IL-6: 1340 ± 242 pg/ml to 177 ± 28.3 pg/ml and 365 ± 64.4 pg/ml, respectively; TNF-α:
2321 ± 362 pg/ml to 413 ± 37.9 pg/ml and 695 ± 44.1 pg/ml, respectively, n= 6, p< 0.05)
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To assess whether PMC influences the tendon-specific
gene expression, we used real time PCR. The expression
of SCX, COL1 and TNMD genes was determined after
treatment with different concentrations of PMC (Fig. 4).
Gene expression analysis confirmed a significant induc-
tion of these genes only at 1 % PMC (3.33 ± 0.48, 12.7 ±
6.55 and 2.4 ± 0.74 respectively, n ≥ 5, p ≤ 0.05).
In order to confirm these results, immunofluorescence
was used as a means of assessing the effect of PMC on
tenocytes. This analysis revealed an increased relative
expression of SCX in tenocytes upon stimulation with
1 % PMC. (The relative x-fold SCX protein expression
was 1.33 ± 0.54 for 1 % PMC, 1.10 ± 0.07 for 5 % PMC
and 1.04 ± 0.06 for 10 % PMC versus 1.0 ± 0.08 for the
control group, n ≥ 5, p ≤ 0.05.) There was no significant
change in TNMD expression after PMC treatment (1.0
± 0.03 for 1 % PMC, 0.95 ± 0.03 for 5 % PMC and 0.98 ±
0.04 for 10 % PMC versus 1.0 ± 0.02 for the control
group; n ≥ 5, p ≤ 0.05) (Fig. 5).
Discussion
Many clinical and laboratory results have been published
that show positive healing effects of orthobiologics like
PRP, stem cells, PRGF, platelet rich fibrin (PRF), and
other platelet compositions in tendon repair [22, 23].
Nevertheless, the different methods of preparing various
platelet compositions do not guarantee the same bio-
logical response. This prevents a suitable comparison of
results [24] [25]. Because the ATR® kit employs a stan-
dardized method to deliver a mediator composition, its
use allows for mutual comparison of results. Such a
standardized method of preparing PMC could provide
an alternative means of achieving similar biological ef-
fects in patients, particularly in a clinical setting.
The results described above demonstrate that PMC con-
tains most of the important mediators in tendon healing:
PDGF-BB, hVEGF, TGF-ß1, BMP-4, BMP-2 and BMP-7.
The concentration of the mediators was considerably
higher than that found in the plasma and serum. PDGF-
BB was increased by a factor of 13, hVEGF by a factor of
24, and TGF-ß1 and BMP-4 each by a factor of 3.
Prior studies had already shown that PDGF-BB exerts
an accelerating effect by stimulating the migration and
proliferation of tenocytes and progenitor cells [14]. Re-
cent in vitro studies have also demonstrated the bac-
teriostatic effect of TGF-ß1 and PDGF-BB in blood
components like PRP [26]. Additionally, TGF-ß1 con-
tributes to the formation of scars as well as fibronectin
expression in tendon healing, which is less positive [27,
28]. VEGF, by contrast, appears to have a somewhat
harmful effect on in vitro tendon healing as it induces
angiogenesis and matrix metalloproteinases (MMPs). It
thus downgrades the material properties of the Achilles
tendon [6]. However, in chronic wounds characterized
by insufficient blood supply, angiogenesis is an import-
ant factor to improve healing, particularly during the
early phase of tendon healing [29].
This study quantified a low level of TNF-α and IL-6 in
PMC. Prior studies have addressed the importance of vari-
ous anti-inflammatory factors during the early phase of
tendon healing. Most recently Ackermann et al. demon-
strated an up-regulation of the anti-inflammatory cyto-
kines IL-6, IL-8 and Il-10 as well as a resolution of the
inflammatory phase two weeks after Achilles tendon rup-
ture in humans [30]. Andersen et al. suggest that IL-6 is
involved in the transformation of mechanical loading into
collagen synthesis [31]. TNF-α is upregulated in tendon
Fig. 2 Cell viability. The cell viability rate was improved by application of PMC to the media. Cell viability was measured using a CTB assay at
3 h (a) and 24 h (b). No effect could be discerned after 3 h; but every concentration of PMC tested led to increased cell viability after 24 h
Fig. 3 Cell proliferation. Tenocyte proliferation increased with PMC
concentration. The cell proliferation assay was measured using
CyQuant cell proliferation assay at 24 h
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lesions and has been found to be an important regulating
factor in that context. It stimulates additional production
of the pro-inflammatory cytokines interleukin 1 beta (IL-
1ß), TNF-α, and anti-inflammatory cytokin IL-10 ,
whereas its expression is reduced in loaded as compared
to unloaded tendon repair [11, 32]. Furthermore TNF-α
leads to suppression of type 1 collagen and to extracellular
matrix (ECM) degradation through stimulation of MMPs.
ECM causes damage and scar formation during tendon
healing. Taken together, pro-inflammatory cytokines seem
to have both positive and negative effects on tendon heal-
ing. As PMC only contains lesser amounts of TNF-α, we
suggest that it acts as less of a trigger of inflammation
after application.
PMC also contains variants BMPs, which have been
described as inducing adipogenic, osteogenic and chon-
drogenic differentiation of mesenchymal stem cells
(MSCs) and tendon-derived stem cells (TDSCs) in vitro
[33]. The addition of PMC to human Achilles tenocytes
leads to a dose-dependent significant enhancement of
tenocyte proliferation and viability. Thus we can exclude
a toxic response.
Tendon tissues harbor a unique cell population,
termed tendon stem/progenitor cells (TSPCs), which has
Fig. 4 Gene expression of SCX, COL1 and TNMD after PMC treatment. Only the addition of 1 % PMC to the tenocyte culture medium showed
significantly increased gene expression of the tenocyte specific markers SCX, COL1 and TNMD as compared to 5 and 10 % PMC supplementation
(SCX: 3.33 ± 0.48 compared to 1.76 ± 0.16 and 2.65 ± 0.90, respectively n = 5; COL1: 12.7 ± 6.55 compared to 8.37 ± 3.75 and 0.94 ± 0.22,
respectively, n≥ 6 , TNMD: 2.7 ± 0.87 compared to 0.86 ± 0.19 and 0.63 ± 0.08, respectively, n ≥ 4, p ≤ 0.05)
Fig. 5 Protein expression of SCX and TNMD after PMC treatment. Protein expressions of SCX (red) and TNMD (red) were detected using
immunofluorescence. Phalloidin staing (green) displayes the cell morphology. The addition of 1 % PMC to the tenocyte culture medium (b, f)
showed significantly increased SCX protein expression in tenocytes. There was no effect on TNMD protein expression. Fluorescence intensity was
measured and quantified using the software Image J. (a and e: 0 %, b and f: 1 %, c and g: 5 %, d and h: 10% PMC)
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universal stem cell characteristics such as self-renewal
capacity. The effect of PMC on TSPCs is not clear [34].
Another major advantage of PMC is that it only involves
mediators without foreign antigens (e.g., blood group anti-
gens, HLA molecules) such as may cause an immunogenic
responses [18]. The great importance of this is shown in an
unpublished paper within our task group proving the apop-
totic effect of platelet poor plasma (PPP) on cells, where
the addition of a minimal quantity of PRP eliminated the
condition. Using real time RT-PCR we were able to quan-
tify the expression of the tendon-typical genes TNMD,
SCX and Col1A1 following treatment of mouse tenocytes
with PMC. Tendons are naturaly a largely avascularized tis-
sue and under physiological condition a high amount of
blood-derived growth factors may not be required. We
could show that lower concentrations of PMC are more ef-
fective in inducing tenogenic marker gene expression than
higher amounts PMC amounts. We hypotheize that a high
amount of growth factors released from platelets are more
suitable for regeneration of high vascularized tissues such
as bone [35] and skin. Schweitzer et al. described SCX as a
differentiation-associated transcription factor expressed in
progenitors and tendon tissue cells. It was found to be an
important factor in early tendon formation [36, 37]. Col1A1
is important for the stability of tendon tissue. With immu-
nohistochemistry we were able to assess the effect of PMC
on tenocytes. The treatment of tenocytes with 1 % PMC
leads to increased SXC expression. There was no significant
difference in TNMD expression after either treatment or
non-treatment of tenocytes with PMC. TNMD is seen as
an important regulator of tenocyte proliferation and in-
volvement in collagen fibril maturation [38].
The distribution of types I and III collagen is critical for
the tensil strength of tendons [39]. We could demonstrate
that a low amount of PMC leads to increased typ I colla-
gen synthesis in monolyer culture. The mechanical prop-
erties of tendons cannot be determined in monolayer
cultivation. Furthermore, tenocytes in monolayer culture
display an unstable phenotype and tend to de-differentiate
[40]. Additional experiments in three-dimensional cul-
tures are nessecary to analyse effects of PMC on pheno-
type differentiation and function of these cells, as well as
the organization of the synthetized collagen network.
It is possible to identify tenocytes in vitro with immu-
nohistochemistry; in culture mediums of higher pas-
sages, tenocytes display a tendency toward phenotypic
drift and dedifferentiation [41–43].
We were able to demonstrate that PMC can be an add-
itional source of the already various expression of en-
dogenous growth factors and cytokines in tendon healing.
Conclusions
As previously discussed, between three and five million
people worldwide are afflicted with tendon and ligament
injuries every year. Achilles tendinopathy is often related to
specific sport injuries caused by inappropriate biomechan-
ical stress. Here we provide evidence that PMC exerts a
biological effect on tenocytes by promoting tenocyte
growth and by upregulating tenogen specific markers. We
hypothesize that low concentrations of PMC can accelerate
the tendon healing and reduce both scar formation as well
as the typically high risk of recurrence upon tendon load-
ing. We intend to explore this question by investigating the
effect of platelet mediators on tenocytes under non-
physiological strain conditions in a bioreactor. Furthermore,
long-term in vitro studies should investigate the effect of
PMC treatment on ECM components. In vivo studies will
be necessary in order to confirm the results.
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